DarioHealth (DRIO)
(Real Time Quote from BATS)
$1.48 USD
-0.02 (-1.33%)
Updated Apr 25, 2024 03:46 PM ET
1-Strong Buy of 5 1
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
DRIO 1.48 -0.02(-1.33%)
Will DRIO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DRIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for DRIO
Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes
DarioHealth files to sell 15.73M shares for holders
DarioHealth files to sell 15.73M shares of common stock for holders
Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution
DarioHealth's cardiometabolic suite selected by two employers